Skip to main content

Menu

BNF March 2022 Update

This update contains 7 significant changes, 2 dose changes, and 3 new monographs.

Significant Changes:

  • COVID-19: updated guidance.
  • COVID-19 vaccines: updated guidance in-line with UK Health Security Agency recommendations.
  • Miconazole: oral gel no longer licensed for treatment of intestinal candidiasis.
  • Obstetrics: updated guidance for the induction of labour.
  • Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error [MHRA/CHM advice].
  • Phosphate imbalance: updated guidance on the use of phosphate-binding agents.
  • Sex hormones: updated guidance on the use of progestogens for the prevention of miscarriage.

Dose Changes:

  • Calcium chloride [update to dosing for treatment of acute severe hyperkalaemia].
  • Mifepristone [update to dosing for induction of labour following intra-uterine fetal death].

New Monographs

  • Jemperli® [dostarlimab]
  • Rybrevant® [amivantamab]
  • Xevudy® [sotrovimab]

For further details on changes in the BNF click on https://www.medicinescomplete.com/#/content/bnf/PHP107699